On Tuesday, Novo Nordisk (NYSE: NVO), a Danish drugmaker, said it has mitigation plans in place to minimize or prevent any disruption to its production due to sea port strikes in the United States.
The maker of popular drugs, Wegovy and Ozempic, plans to ship its products to and from the U.S. via air freight, a company spokesperson said.
The company imports some of its active pharmaceutical ingredient, or semaglutide, into the U.S. for its blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy, according to CNBC, which first reported on the mitigation plans.
Earlier on Tuesday, the U.S. Department of Health and Human Services (HHS) said its preliminary analysis showed a strike by U.S. East Coast and Gulf Coast dockworkers should have limited impact on the availability of essential goods such as medicines and medical devices.
The dockworkers began their first large-scale stoppage in nearly 50 years, halting about half the country’s ocean shipping after negotiations for a new labor contract broke down over wages.
(Source: Reuters)
Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.